Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients

Genomic impact of transient low-dose decitabine treatment on primary AML cells

(2013) J. M. Klco et al.   BLOOD

Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR

(2012) N Imahashi et al.   BONE MARROW TRANSPLANTATION

Mixed Effects Modeling of Proliferation Rates in Cell-Based Models: Consequence for Pharmacogenomics and Cancer

(2012) Hae Kyung Im et al.   PLoS Genetics

Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study

(2011) H. Kang et al.   BLOOD

Genetic Variation Predicting Cisplatin Cytotoxicity Associated with Overall Survival in Lung Cancer Patients Receiving Platinum-Based Chemotherapy

(2011) X.-L. Tan et al.   CLINICAL CANCER RESEARCH

Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

(2011) R. Stephanie Huang et al.   CLINICAL CANCER RESEARCH

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants

(2011) L. D. Ward et al.   NUCLEIC ACIDS RESEARCH

Chemotherapeutic-induced apoptosis

(2011) Yujia Wen et al.   Pharmacogenetics and Genomics

Pharmacogenomics of cytarabine in childhood leukemia

(2011) Jatinder K Lamba   PHARMACOGENOMICS

Genome-Wide Local Ancestry Approach Identifies Genes and Variants Associated with Chemotherapeutic Susceptibility in African Americans

(2011) Heather E. Wheeler et al.   PLoS One

LocusZoom: regional visualization of genome-wide association scan results

(2010) R. J. Pruim et al.   BIOINFORMATICS

METAL: fast and efficient meta-analysis of genomewide association scans

(2010) C. J. Willer et al.   BIOINFORMATICS

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Crosstalk of EDA-A2/XEDAR in the p53 Signaling Pathway

(2010) C. Tanikawa et al.   MOLECULAR CANCER RESEARCH

Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines

(2010) A L Stark et al.   PHARMACOGENOMICS JOURNAL

Genetics and Beyond – The Transcriptome of Human Monocytes and Disease Susceptibility

(2010) Tanja Zeller et al.   PLoS One

Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci

(2010) E. R. Gamazon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SCAN: SNP and copy number annotation

(2009) Eric R. Gamazon et al.   BIOINFORMATICS

Acute myelogenous leukemia

(2009) Joshua L. Shipley et al.   EXPERIMENTAL HEMATOLOGY

Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia

(2009) Jun J. Yang   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway

(2009) C Tanikawa et al.   ONCOGENE

Genetic factors influencing cytarabine therapy

(2009) Jatinder K Lamba   PHARMACOGENOMICS

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity

(2008) C. M. Hartford et al.   BLOOD